- Trillium Therapeutics (NASDAQ:TRIL) has entered into a second amended and restated license agreement with University Health Network and The Hospital for Sick Children (the “Licensors”).
- Under the agreement, the sublicense revenues were removed in return for a payment of C$3M to the Licensors in the form of 369,621 common shares.
- Under the original license agreement, Trillium was required to pay to the Licensors 20% of the first C$50M of sublicensing revenues, and an additional 15% over the first revenue. On the issuance of common shares, Trillium will retain 100% of any potential future sublicense revenues, other than royalties on net sales.